近年来，免疫治疗已成为肿瘤治疗领域的主要研究重点。由于其良好的疗效和持久的免疫应答，免疫检查点抑制剂已经使得许多类型的癌症患者获益于长期生存。然而，免疫系统的过度激活可能会攻击正常器官并引起一系列免疫相关的不良反应。其中，由于免疫相关性结肠炎的高发率，值得特别关注。曲美单抗是一种由江苏恒瑞医药公司开发的PD-1抑制剂。我们报告了一例曲美单抗治疗后出现免疫相关性结肠炎的肝细胞癌患者的临床数据。一名63岁的男性肝细胞癌患者，在接受4个周期曲美单抗治疗后出现腹泻和便血。内镜检查显示终末回肠和全结肠黏膜上有多个鳞片状充血和水肿，表面鲜红。病理学评估显示结肠黏膜慢性炎症。口服肠溶性磺唑沙宗片0.25g，每日2次，持续6周后，患者的结肠炎症得到改善。曲美单抗可引发免疫相关性结肠炎，磺唑沙宗可用来减少糖皮质激素的不良反应。 © 2023 Cheng等

In recent years, immunotherapy has become a major research focus in the field of cancer treatment. Because of its good efficacy and lasting immune response, immune checkpoint inhibitors have benefited the long-term survival of many types of cancer patients. However, overactivation of the immune system may attack normal organs and cause a series of immune related adverse reactions. Among them, due to the high incidence of immune-related colitis, it deserves special attention. Camrelizumab is a programmed cell death 1 (PD-1) inhibitor that was developed by Jiangsu Hengrui Medicine Company. We reported the clinical data of a case of hepatocellular carcinoma with immune-related colitis after treatment with camrelizumab. A 63-year-old man with hepatocellular carcinoma developed diarrhea and hematochezia after receiving 4 cycles of camrelizumab. Endoscopy showed multiple flake congestion and edema in the terminal ileum and total colon mucosa with bright red surface. Pathological evaluation showed chronic inflammation of colonic mucosa. After giving 0.25g bid of enteric-coated sulfasalazine tablets orally for 6 weeks, his colitis improved. Camrelizumab can induce immune-related colitis. Sulfasalazine could be used to reduce adverse reactions of glucocorticoids.© 2023 Cheng et al.